CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL. The latter represent lymphomas derived from cytotoxic T-cells, as recently described in the revised 2017 WHO Classification. Unlike cutaneous lesions, immunochemotherapy is indicated if curative intent is possible.